News and Trends 8 Sep 2022
First patient dosed in China trial with drug to treat non-Hodgkin lymphoma
The dosing of the first patient at a clinical trial in China for patients with relapsed/refractory non-Hodgkin lymphoma (NHL) was announced yesterday (September 7). CASI Pharmaceuticals and BioInvent International AB…
